132219-51-3Relevant articles and documents
N-formamido pyrazoline derivative serving as P2X3 receptor antagonist and application thereof
-
Paragraph 0118; 0123-0124; 0125; 0127, (2020/11/23)
The invention discloses an N-formamido pyrazoline derivative, a compound represented by a general formula (I) or an enantiomer, a diastereoisomer, an epimer, a racemate or pharmaceutically acceptablesalt thereof. The compound is an antagonist of a ligand gated non-selective cationic channel receptor subtype P2X3, and can be used for treating or preventing various diseases mediated by a P2X3 receptor.
Effective conversion of heteroaromatic ketones into primary amines via hydrogenation of intermediate ketoximes
Baucom, Kyle D.,Guram, Anil S.,Borths, Christopher J.
, p. 201 - 204 (2015/03/03)
A process to access heteroaromatic primary amines from the corresponding heteroaromatic ketones has been developed. A broad range of previously reported methods to convert ketones to primary amines was examined on heterocyclic ketones without success, including Leuckart-Wallach conditions, borane reductions, and transition-metal-catalyzed hydrogenations. Unique among the catalysts examined, Raney cobalt produced the desired primary heterocyclic amine. Raney cobalt hydrogenation of structurally varied heterocyclic ketoximes was demonstrated to form primary amines in good selectivity under mild conditions, and the products are easily isolated in high yield. Additionally, this is the first report of a systematic evaluation of the capabilities of Raney cobalt as an oxime hydrogenation catalyst.
IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER
-
Page/Page column 16, (2008/12/06)
The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3- trifluoropropylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2- cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1- azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or a pharmaceutically acceptable salt thereof.
TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS
-
, (2009/01/20)
The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
Morpholine type cinnamide compound
-
Page/Page column 63, (2008/06/13)
The present invention relates to a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein R1, R2, R3, and R4 are the same or different and each represent a hydrogen atom or a C1-6 alkyl group; X1 represents a C1-6 alkylene group that may be substituted; Xa represents a methoxy group or a fluorine atom; Xb represents an oxygen atom or a methylene group, provided that Xb is only an oxygen atom when Xa is a methoxy group; and Ar1 represents an aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group that may have a substituent such as a halogen atom; and to use of the compound or salt as a pharmaceutical agent.
Insecticidally active nitro guanidine compounds
-
, (2008/06/13)
Insecticidal novel nitro compounds of the formula STR1 in which R1 and R2 are hydrogen or C1-4 alkyl, R3 is --S--R4 or STR2 in which R4 is C1-4 alkyl, R5 and R6 are hydrogen or C1-4 alkyl, Y is CH or N, and Z is a five- or six-membered heterocyclic group having at least one nitrogen atom which may be substituted by halogen or C1-4 alkyl, provided that where Y is CH, then R1 is C1-4 alkyl.
